ABSTRACT
Objective @#To assess the risk of importation and local transmission of Ebola hemorrhagic fever（EHF）in Jinhua,and to provide reference for prevention policy making.@*Methods @#We collected the information of EHF cases,immigration data and EHF response capacity of Jinhua,then invited 18 experts from Jinhua Entry-Exit Inspection and Quarantine Bureau,Exit-Entry Administration Division of Public Security Bureau and Centers for Disease Control and Prevention in Jinhua. According to the risk assessment criteria recommended by World Health Organization,the risk of EHF importation and local transmission in Jinhua was assessed qualitatively by expert consultation,and the probability of local transmission after EHF importation was assessed quantitatively by compartment model.@*Results @#The results of expert consultation showed that the average scores of possibility and severity of EHF importation in Jinhua was 1.7 and 2.1,which was at low risk after substituted into the risk matrix. The risk of EHF importation in urban areas of Jinhua and Yiwu,where there were more African people,was higher than that in other counties or districts. The average scores of possibility and severity of local transmission was 1.9 and 3.1,which was at medium risk after substituted into the risk matrix. The results of compartment model analysis showed that the possibility of local transmission after the importation of EHF was related to the time interval between the onset of the epidemic and the effective isolation of the imported cases. When the interval was within 2 days,the risk of local transmission was low,but when it exceeded 4 days,the imported epidemic was easy to spread and lead to local transmission.@*Conclusion @#The EHF importation in Jinhua was at low risk;the local transmission caused by imported cases was at medium risk,but was less likely to cause large-scale transmission. Early identification of EHF cases was the key to reducing the risk of local transmission.
ABSTRACT
Ebola hemorrhagic fever is an acute infectious disease caused by Ebola virus,the mor-tality rate of which is up to 90% . Due to its high infection rate,high mortality rate as well as being a serious threat to public health and safety,Ebola virus is listed as a World Health Organization Risk Group 4 Patho-gen(requiring Biosafety Level 4-equivalent containment). However,there is no effective control method and treatment for Ebola virus infection. Different approaches have been used to develop vaccines and therapeutic drugs against Ebola virus infection and clinical trials of some products have been initiated,such as ZMapp, BCX-4430,GS-5734,DNA vaccines,and adenovirus vector vaccines. National Institutes of Health(NIH) announced a successful development of vaccine for Ebola virus which had passed the clinical trial by the end of 2014. At the meantime,the first anti-Ebola virus medicine had also been approved in China for emergency use only. Recent advances in the research and development of therapeutic drugs and vaccines against Ebola virus will be described in this review.
ABSTRACT
Ebola hemorrhagic fever, caused by the highly virulent RNA virus of the filoviridae family, has become one of the world's most feared pathogens. The virus induces acute fever and death, often associated with hemorrhagic symptoms in up to 90% of infected patients. The known sub-types of the virus are Zaire, Sudan, Taï Forest, Bundibugyo and Reston Ebola viruses. In the past, outbreaks were limited to the East and Central African tropical belt with the exception of Ebola Reston outbreaks that occurred in animal facilities in the Philippines, USA and Italy. The on-going outbreak in West Africa that is causing numerous deaths and severe socio-economic challenges has resulted in widespread anxiety globally. This panic may be attributed to the intense media interest, the rapid spread of the virus to other countries like United States and Spain, and moreover, to the absence of an approved treatment or vaccine. Informed by this widespread fear and anxiety, we analyzed the commonly used strategies to manage and control Ebola outbreaks and proposed new approaches that could improve epidemic management and control during future outbreaks. We based our recommendations on epidemic management practices employed during recent outbreaks in East, Central and West Africa, and synthesis of peer-reviewed publications as well as published "field" information from individuals and organizations recently involved in the management of Ebola epidemics. The current epidemic management approaches are largely "reactive", with containment efforts aimed at halting spread of existing outbreaks. We recommend that for better outcomes, in addition to "reactive" interventions, "pre-emptive" strategies also need to be instituted. We conclude that emphasizing both "reactive" and "pre-emptive" strategies is more likely to lead to better epidemic preparedness and response at individual, community, institutional, and government levels, resulting in timely containment of future Ebola outbreaks.
Subject(s)
Humans , Disease Outbreaks , Hemorrhagic Fever, Ebola/epidemiology , Africa/epidemiology , Hemorrhagic Fever, Ebola/prevention & control , Hemorrhagic Fever, Ebola/transmissionABSTRACT
Ebola,known as Ebola hemorrhagic fever,is caused by infection with a virus of the fami-ly Filoviridae,genus Ebolavirus. Ebola is circulating in some of the west Africa countries and causing outb-reacks and epidemic with high mortality. The virus can be spread in humans by direct contact with blood or body fruit of infected one through broken skin or mucous membranes. The virus can not be spread by air or water. The symptoms of Ebola include fever,severe headache,muscle pain,weakness,fatigue,diarrhea,vomi-ting,abdominal( stomach) pain and unexplained hemorrhage. Symptoms of Ebola and complications are trea-ted as they appear. Recovery from Ebola depends on good supportive care and the patient′s immune response. Those people recovered from Ebola developed antibodies against Ebola virus and last long period. No ap-proved vaccine or medicine is available for Ebola.
ABSTRACT
Since the first case of Ebola virus disease (EVD) in Guinea was reported in March 2014 by World Health Organization (WHO), the outbreak has continued through the year and the total number of 19,065 patients was reported as the confirmed or suspected in the EVD-affected countries. Among the cases, 7,388 patients were reported death by 19 December. Currently, available therapeutics to treat the infected patients or vaccines to prevent people from infection is not developed yet while viral diagnostic methods were already developed and firmly established in a lot of countries as a first step for the preparedness of Ebola outbreak. Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD. Several candidates of vaccines also were investigated their efficacy in animal models by National Institute of Health (NIH) and Department of Defense, and they are processing of clinical tests in West Africa aiming to finish the development by the 2015. Vaccine and therapeutic development is essential to stop the EVD outbreak in West Africa, also to protect the world from the risk which can be generated by potential spread of Ebola virus.
Subject(s)
Humans , Africa, Western , Ebolavirus , Guinea , Hemorrhagic Fever, Ebola , Models, Animal , Vaccines , World Health OrganizationABSTRACT
The current outbreak of Ebola virus in West Africa has become a devastating problem, with a mortality rate around 51%; over 3 132 deaths have been confirmed and even more are expected in this case. The virus causes a characteristic disease known as hemorrhagic fever. Its symptoms range from nonspecific signs such as fever, to more specific problems such as serious bleeding. Transmission occurs easily when a person comes in contact with contaminated fluids. Treatment is supportive because there are still no specific drugs for use. The present review focuses on the main features related to the Ebola virus, its transmission, pathogenesis, treatment and control forms. There is little in-depth knowledge about this disease, but its severity requires attention and information to prevent a worse scenario than the current.
ABSTRACT
The current outbreak of Ebola virus in West Africa has become a devastating problem, with a mortality rate around 51%; over 3132 deaths have been confirmed and even more are expected in this case. The virus causes a characteristic disease known as hemorrhagic fever. Its symptoms range from nonspecific signs such as fever, to more specific problems such as serious bleeding. Transmission occurs easily when a person comes in contact with contaminated fluids. Treatment is supportive because there are still no specific drugs for use. The present review focuses on the main features related to the Ebola virus, its transmission, pathogenesis, treatment and control forms. There is little in-depth knowledge about this disease, but its severity requires attention and information to prevent a worse scenario than the current.
ABSTRACT
The outbreak of Ebola hemorrhagic fever in West Africa in February 2014 is the worst one in the history of the disease.Medicines and vaccines for Ebola have attracted special attention .This study utilizes Cortellis database of Thom-son Reuters and knowledge about Ebola virus to analyze current R&D of medicines and vaccines for Ebola in order to offer references for research and development .Study findings shows that there are mainly 5 important categories:vaccines, neu-tralizing antibodies , small-molecule anti-Ebola drugs , RNAi drugs and nucleotide drugs .In each category , there are prom-ising products under development that are worthy of attention .
ABSTRACT
In 2014,serious Ebola fever epidemic broke out in West Africa .Afterwards, the US transported two Ebola patients from Liberia by air, which aroused world wide concern .During the aeromedical evacuation , there were lots of tech-nical problems and management procedures involved .First, the US government toke emergency measures for the patients in a local hospital ,which made evacuation possible .Secondly , the US CDC and other government departments coordinated this matter during and after the evacuation .Finally,upon arrival at home the two patients received careful isolation and treat-ment.Thus, the successful aeromedical evacuation is instructive for us .